ClinicalTrials.gg
Not yet recruitingNCT06267300Updated Feb 28, 2024

Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial

A Phase 3 interventional study of Hyperbaric oxygen in Post-COVID-19 Syndrome, Post-COVID Syndrome and Post COVID-19 Condition, sponsored by Erasmus Medical Center. Not yet recruiting at 7 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.

Started
2024
with 1 other
Phase 3
3 of 15
3 open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Erasmus Medical Center

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 2 that started in 2024, is one of 3 in phase 3, and was the 8th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action.

The main questions it aims to answer are:

  • What is the clinical relevance of improvements of symptoms and quality of life after treatment with HBOT for post-COVID?
  • What are the changes in absence from work after treatment with HBOT?
  • What is the cost-effectiveness of treatment with HBOT?
  • What are possible mechanisms of action of HBOT?

Participants will undergo 40 sessions of HBOT. Researchers will compare HBOT with standard care alone (control group). In case of a positive outcome, patients in the control group can cross-over to the HBOT group after 6 months.

03

Conditions studied

  • Post-COVID-19 Syndrome
  • Post-COVID Syndrome
  • Post COVID-19 Condition
  • Post-COVID Condition
  • Post COVID-19 Condition, Unspecified
  • Long COVID
  • Long Covid19

Keywords

  • clinical relevance
  • quality of life
  • absence from work
  • cost-effectiveness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cognitive and/or physical symptoms ≥ 12 months after acute COVID-19 infection
  • Symptoms include post-exertional malaise (PEM) and/or dysautonomia as assessed by questionnaires and/or NASA LEAN test
  • Symptoms affect day-to-day life (based on SF-36 'role limitations due to physical functioning' score of ≤ 50 at baseline).
  • Current treatment regimen is stable for at least 1 months before inclusion

Exclusion criteria

Exclusion Criteria:

  • Unfit for hyperbaric treatment
  • Previous diagnosis of ME/CFS
  • Unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Hyperbaric Oxygen therapy

    40 sessions of HBOT at 2.4 ATM

    Drug: Hyperbaric oxygen

  • No intervention
    Standard care

Interventions

  • Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)

    Also known as: HBO, HBOT, Hyperbaric oxygen therapy

06

What researchers measure

Primary outcomes

  1. Physical and mental component scores of the 36-item Short Form Survey (SF-36)

    Range 0-100, with higher scores indicating higher quality of life

    Time frame: Week 20 (i.e. 3-months after end of HBOT)

Secondary outcomes

  1. Euroqol-5D (EQ-5D)

    Descriptive for 5 dimensions + visual analogue score (VAS, range 0-100 with higher scores indicating higher quality of life)

    Time frame: Week 0/4/8/20/34 (i.e. at start of HBOT, halfway during treatment, directly after treatment and 3 and 6 months after treatment).

  2. Activity tracking (through wrist band), monitoring heart rate, step count and sleep patterns

    Time frame: Worn continuously until week 34

  3. Biochemical parameters

    Time frame: Week 0, 8 and 34 (i.e. at start of HBOT, directly after HBO and 3-months after treatment)

  4. Absence from work

    Time frame: Week 0/4/8/20/34 (i.e. at start of HBOT, halfway during treatment, directly after treatment and 3 and 6 months after treatment).

  5. Cost-effectiveness

    Time frame: Week 0/4/20/34 (i.e. at start of HBOT, directly after treatment and 3 and 6 months after treatment).

07

Study locations

7 sites
  • Da Vinci Clinic
    Amersfoort, Netherlands
  • Da Vinci Clinic
    Geldrop, Netherlands
  • Da Vinci Clinic
    Hoogeveen, Netherlands
  • HGC Rijswijk
    Rijswijk, Netherlands
    • Rutger Lalieu, Dr. · Contact
  • Da Vinci Clinic
    Rotterdam, Netherlands
    • Nina Lansdorp, Dr. · Contact
  • Erasmus MC
    Rotterdam, Netherlands
    • Merel Hellemons, Dr. · Contact
  • Da Vinci Clinic
    Waalwijk, Netherlands
    • Nina Lansdorp, Dr. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 20, 2024
StartEst.
Oct 1, 2024
Primary completionEst.
Oct 1, 2025
CompletionEst.
Apr 1, 2026
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06267300
Collaborators
Da Vinci Clinic, HGC Rijswijk
Responsible party
Merel Hellemons (Dr., Erasmus Medical Center) — Principal investigator
First posted
Feb 20, 2024
Start date
Oct 1, 2024 (estimated)
Primary completion
Oct 1, 2025 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyperbaric Oxygen

Start the discussion